Home / Conferences

Conferences

Report on 25th Annual EuroMeeting, 4-6 March 2013, Amsterdam, The Netherlands

Delegates at DIA’s 25th Anniversary of the EuroMeeting, held on 4–6 March 2013 in Amsterdam, The Netherlands, were offered the mouth watering prospect of more than 100 sessions across 17 themes, addressed by 300+ Speakers from EMA, European Commission, FDA and other national regulatory agencies. Most popular sessions included Implementation of the New Pharmacovigilance Legislation, the Regulatory Town Hall Meeting and the sell-out European Landscape on HTA - the EUnetHTA Joint Action. Eighteen pre-conference tutorials were led by an expert faculty and 120 students, young professional and patients all attended sessions created especially for them.

Patient power predominates at DIA Europe’s Clinical Forum

DIA Europe’s 2012 Clinical Forum in October this year promises to be an important multidisciplinary conference for all engaged in the clinical development and therapeutic use of medicines. The theme for 2012 is ‘The Empowered Patient’, an acknowledgement of the inescapable fact that the evolution of technology and electronic communication has given patients the ability to find and share health information which will impact their treatment choices – empowering them to become more engaged in their care and to participate in decisions about it.

Need for global development programme for biosimilars

There is now a crucial need for a framework that allows global biosimilars development.

European Commission calls for wider use of generic medicines

At the 10th International Symposium on Biosimilar Medicines, organised by the European Generics medicines Association, held in London, UK, on 19–20 April 2012; the European Commission (EC) highlighted the need to stimulate wider use of generic medicines.

Removal of barriers for the global development of biosimilars

At the 2012 Biosimilars Medicines: 10th EGA International Symposium, held in London, UK, on 19–20 April 2012; Mr Nils Behrndt (Deputy Head of Cabinet DG Sanco, European Commission) announced that the European Commission (EC) wishes to stimulate the global development of biosimilars. The EC has thereby two objectives:

Europe must seize new opportunities in biosimilars and generics

Opportunities for increased employment and growth in the generic and biosimilar medicines markets should be exploited in order to avoid Europe falling behind other regions according to the European Generic medicines Association (EGA).

EGA meeting London 2011: biosimilars competitiveness in the EU

At its 9th International Symposium on Biosimilar Medicines held in London, UK, on 14-15 April 2011 the European Generic medicines Association (EGA) highlighted the need for an EU industrial policy to enhance the competitiveness of biosimilars.

Pharmacokinetics, bioequivalence of cyclobenzaprine tablets

Cyclobenzaprine is a muscle relaxant, structurally related to first-generation tricyclic antidepressants. At the 2008 World Congress of Pharmacy and Pharmaceutical Sciences held 29 August – 4 September 2008 in Basel, Switzerland, Ms Tatiane Maria de Lima Souza Brioschi et al. of the University of Sao Paolo in Brazil presented a poster entitled ‘Pharmacokinetics and bioequivalence evaluation of cyclobenzaprine tablets’ in which the bioequivalence of two brands of cyclobenzaprine 10 mg tablets in healthy volunteers was evaluated.

Bioavailability and bioequivalence norms in Latin America

At the 2008 World Congress of Pharmacy and Pharmaceutical Sciences held 29 August – 4 September 2008 in Basel, Switzerland, Mr Luis Enrique Morena Exebio of the National Institutes of Health (NIH) in Peru, presented a poster entitled ‘Investigation’s ethical aspects regarding pharmaceutical products bioavailability and bioequivalence in Latin American legislation’.

Overcoming protein-production hurdles: Glycosylation

In a Genetic Engineering & Biotechnology News Feature Article of 1 June 2009, Mr John Morrow Jr discusses protein-production hurdles for biologicals, which was a key theme at IBC’s “Bioprocessing Meeting”, held in La Costa, CA, USA in 2009.

Generics News Research General

more

Biosimilars News Research General

more